Last updated: 11/07/2018 00:54:30
Topotecan and vinorelbine in advanced nonsmall cell lung cancer
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Topotecan and vinorelbine in advanced nonsmall cell lung cancer
Trial description: Topotecan and vinorelbine in advanced nonsmall cell lung cancer
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Green SJ, Dahlberg S. , Planned versus Attained Design in Phase II Clinical Trials. Statistics in Medicine; 1992; 11:853-862
Grunberg, et al. An open label, multicenter, non-comparative phase II study of weekly intravenous vinorelbine (V) and topotecan (T) in chemotherapy-naive patients (pts) with advanced non-small cell lung cancer (NSCLC), Lung Cancer 49 (2), 2005 Abstract S245
Stupp R, Bauer L, Perey N, et al. , Topotecan and Vinorelbine is as Effective but Less Toxic than Platinum-Containing Regimens Against NSCLC. Promising Results of this Outpatient Regimen in a Phase II Trial. Lung Cancer, 2000;29, (Abstract 114)
Vivacqua J, Lebedda WA, Keogh MM, et al., Phase I/II Study of Sequential Interferon Alpha-2b (Inf-a2b) and Weekly Topotecan/Vinorelbine in Advanced Non-Small Cell Lung Cancer. Proc. Am. Soc. Clin. Oncol. 2002;21:226b (Abstract 2721)
Medical condition
Lung Cancer, Non-Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
September 2002 to June 2004
Type
Not applicable
Phase
1/2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2004-30-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website